Search Results

You are looking at 91 - 100 of 431 items for :

  • "Adjuvant therapy" x
  • All content x
Clear All
Full access

Harold J. Burstein

percentage. Of course, a few caveats are warranted. The bulk of these reports are derived from studies of women taking adjuvant therapy for hormone receptor-positive breast cancer. Such patients often have a favorable prognosis and might reasonably be

Full access

Michelle T. Ashworth and Adil Daud

and MEK inhibitors, and effective adjuvant therapies can be expected to increase the impact of accurate staging with SLNB on overall survival. At the time of metastasis to lymph nodes in 2002, the patient was treated with complete lymphadenectomy

Full access

Joleen M. Hubbard and Axel Grothey

% of patients undergoing total colectomy will have 5 or more bowel movements per day, and 30% will have issues with fecal incontinence. 34 , 35 Adjuvant Therapy for Stage II and III Colon Cancer Patients with high-risk stage II and III disease

Full access

Kathleen Harnden and Kimberly Blackwell

recent prospective trial to date evaluating zoledronic acid in addition to standard adjuvant therapy in ESBC. 21 At the final efficacy analysis after a median follow-up Table 1 Characteristics of Published Phase III Trials With Zoledronic Acid

Full access

Clayton A. Smith and Lisa A. Kachnic

improve 10-year OS compared with observation (51.8% vs 48.4%; P =.32). 13 Although early analysis demonstrated a DFS benefit of adjuvant therapy for patients with ypT0–2 (hazard ratio [HR], 0.64; 95% CI, 0.45–0.91; P =.13), this benefit was not observed

Full access

Ami Vyas, S. Suresh Madhavan, Usha Sambamoorthi, Xiaoyun (Lucy) Pan, Michael Regier, Hannah Hazard, and Sita Kalidindi

, radiotherapy (RT), and adjuvant therapy. 2 – 6 Regardless of these extensive costs to Medicare, there is insufficient up-to-date information on healthcare utilization and costs incurred by specific services, and factors significantly contributing to these

Full access

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag, and Tanios Bekaii-Saab

the question as to the utility of the current standard of care, which is 6 months of perioperative systemic therapy. Given the unclear utility of adjuvant therapy after preoperative therapy has been administered, the clinical importance of pathologic

Full access

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

dissection for melanoma . J Clin Oncol 2004 ; 22 : 3677 – 3684 . 70 Cascinelli N Belli F MacKie RM . Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised

Full access

Donna Trauth and Lori J. Goldstein

1998 ; 17 : 101 . 65 Eifel P Axelson JA Costa J . National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3 2000 . J Natl Cancer Inst 2001 ; 93 : 979 . www

Full access

David S. Ettinger

fusion gene EML-4 ALK . This mutation seems to be mutually exclusive with the EGFR and KRAS mutation in the phase I study. Adjuvant Therapy In 2004, the International Adjuvant Lung Cancer Trial showed an approximately 5% survival advantage